Granulatimide | 219828-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Granulatimide
• 英文别名: 3,5,9,19-tetrazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1,4,6,11,13,15,17-heptaene-8,10-dione
• CAS: 219828-99-6
• 化学式: C₁₅H₈N₄O₂
• 分子量: 276.254
• InChiKey: LBTREMHIJGMYQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  17-(methoxymethyl)granulatimide 在 盐酸 作用下， 反应 2.0h， 以72%的产率得到Granulatimide
  参考文献：
  名称：

  格拉那肽及其结构类似物的新合成途径。

  摘要：

  在PdCl（2）（PPh（3））（2）存在的条件下，斯坦尼吲哚12与4-碘咪唑13（或24）的Stille偶联反应得到相应的吲哚-咪唑偶联产物14（或25），从而得到一种新的合成方法，从巴西海生的Didemnum granulatum及其结构类似物10-甲基颗粒剂（23），17-甲基颗粒剂（30），10,17-二甲基颗粒剂（31）中分离得到了生物碱颗粒剂（7）。

  DOI：

  10.1248/cpb.50.872

文献信息

• [EN] PYRROLE-2,5-DIONE DERIVATIVES FOR THE TREATMENT OF DIABETES<br/>[FR] DERIVES DE PYRROLE-2, 5-DIONE DESTINES AU TRAITEMENT DU DIABETE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001074771A1

  公开（公告）日：2001-10-11

  A method for the treatment of conditions associated with a need for inhibition of GSK-3, which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein R1 is a substituted or unsubstituted carbocyclic or heterocyclic aromatic ring, which ring may be fused to a substituted or unsubstituted carbocyclic or heterocyclic aromatic or non-aromatic ring; R2 is a substituted or unsubstituted carbocyclic or heterocyclic aromatic ring, which ring may be fused to a substituted or unsubstituted carbocyclic or heterocyclic aromatic ring, with the proviso that R2 is not 3-indolyl or a fused-ring derivative of 3-indolyl; R3 is hydrogen, or R?1 and R3¿ together with the nitrogen atom to which they are attached form a fused substituted or unsubstituted heterocylic ring; to a human or non-human mammal in need thereof.

  一种用于治疗需要抑制GSK-3的病症的方法，该方法包括向需要治疗的人类或非人哺乳动物中投与一种公认为药用的衍生物或化合物(I)的有效、非毒性剂量，其中R1是取代或未取代的碳环或杂环芳香环，该环可能与取代或未取代的碳环或杂环芳香环或非芳香环融合；R2是取代或未取代的碳环或杂环芳香环，该环可能与取代或未取代的碳环或杂环芳香环融合，但R2不是3-吲哚基或3-吲哚基的融合环衍生物；R3是氢，或R1和R3与它们连接的氮原子一起形成融合的取代或未取代的杂环环。
• Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases
  申请人：International Stem Cell Corporation

  公开号：US10039794B2

  公开（公告）日：2018-08-07

  The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.

  本发明部分基于治疗神经退行性疾病和失调的方法。具体而言，本发明公开了利用神经干细胞（NSC）和/或多能干细胞（PSC）衍生的神经元或神经元前体细胞治疗神经退行性疾病的方法。本发明还公开了诱导内源性多巴胺能神经元释放多巴胺并提高受试者体内多巴胺水平的方法。
• Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis
  作者：Hubert Lavrard、Frédéric Rodriguez、Evelyne Delfourne

  DOI：10.1016/j.bmc.2014.06.028

  日期：2014.9

  The two marine alkaloids granulatimide and isogranulatimide have been shown to inhibit the checkpoint kinase 1 (Chk1), a promising target for cancer treatment. A molecular docking study allowing the design of new potential Chk1 inhibitors based on the natural products skeleton and the synthetic work to an amino-target platform to prepare them are described.
• Granulatimide and Isogranulatimide, Aromatic Alkaloids with G2 Checkpoint Inhibition Activity Isolated from the Brazilian Ascidian <i>Didemnum </i><i>granulatum</i>:  Structure Elucidation and Synthesis
  作者：Roberto G. S. Berlinck、Robert Britton、Edward Piers、Lynette Lim、Michel Roberge、Rosana Moreira da Rocha、Raymond J. Andersen

  DOI：10.1021/jo981607p

  日期：1998.12.1

  Crude methanol ex-tracts of the ascidian Didemum granulatum collected in Brazil showed activity in a new screen for G2 cell cycle checkpoint inhibitors. Bioassay-guided fractionation of the extract yielded the known alkaloids didemnimides A (1) and D (2), the new alkaloid didemnimide E (3), and a new G2 checkpoint inhibitor. Two candidate structures for the inhibitor, named granulatimide (4) and isogranulatimide (5), have been prepared via a short and efficient biomimetic synthesis involving the photolysis of didemnimide A (1). The synthesis revealed that the correct structure for the naturally occurring G2 checkpoint inhibitor is isogranulatimide (5). Granulatimide (4), the other candidate structure, was also found to be a G2 checkpoint inhibitor, and it was subsequently detected in chromatographic fractions associated with purification of D. granulatum alkaloids. Granulatimide (4) and isogranulatimide (5) represent the first examples of a new class of G2 specific cell cycle checkpoint inhibitors and the first ones identified through a rational screening program.
• GRANULATIMIDE DERIVATIVES FOR USE IN CANCER TREATMENT
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：EP1070068A1

  公开（公告）日：2001-01-24

表征谱图